Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $1.4 million.

  • Anika Therapeutics' Depreciation & Amortization (CF) fell 25.22% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 19.25%. This contributed to the annual value of $6.9 million for FY2024, which is 6.99% up from last year.
  • As of Q3 2025, Anika Therapeutics' Depreciation & Amortization (CF) stood at $1.4 million, which was up 8.67% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q3 2024 and a low of $1.3 million during Q2 2025.
  • Over the past 3 years, Anika Therapeutics' median Depreciation & Amortization (CF) value was $1.6 million (recorded in 2023), while the average stood at $1.6 million.
  • The largest annual percentage gain for Anika Therapeutics' Depreciation & Amortization (CF) in the last 5 years was 184.43% (2021), contrasted with its biggest fall of 58.33% (2021).
  • Anika Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $1.8 million in 2021, then decreased by 3.26% to $1.7 million in 2022, then decreased by 5.35% to $1.6 million in 2023, then declined by 4.18% to $1.6 million in 2024, then declined by 25.22% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.4 million during Q1 2025.